Proteomic Biomarkers Predict ALS Symptom Onset in Genetic Carriers

A longitudinal proteomic analysis of plasma from unaffected carriers of ALS-associated pathogenic variants can predict the timing of phenoconversion to clinically manifest amyotrophic lateral sclerosis, according to a study published July 27, 2026, in Nature Medicine. The research identified early protein changes in the blood that occur before the onset of physical symptoms.

The study focused on individuals who carry genetic mutations linked to ALS but have not yet developed the disease. By tracking protein levels in the plasma over time, researchers mapped the trajectories of these biomarkers to determine when a carrier would likely transition from an unaffected state to showing clinical symptoms of the disease.

Plasma Proteomics and ALS Phenoconversion

Proteomics involves the large-scale study of proteins, which serve as the functional tools of the cell. In this research, published in Nature Medicine, the team utilized longitudinal plasma proteomics to detect biochemical shifts that precede the muscle weakness and atrophy characteristic of ALS.

The data indicates that specific protein signatures change in a predictable manner before the clinical onset of the disease. These changes allow for the mapping of trajectories that can be used to estimate the window of phenoconversion, the point at which a genetic carrier becomes a patient with manifest ALS.

Biomarker Identification in Genetic Carriers

The research targeted carriers of pathogenic variants, meaning individuals with known genetic predispositions to ALS. By analyzing plasma samples at multiple time points, the study identified protein fluctuations that distinguish those nearing symptom onset from those who remain stable.

These plasma-based biomarkers provide a non-invasive method to monitor the progression of the disease at a molecular level.

Clinical Implications for Neurodegenerative Research

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of motor neurons.

The findings in Nature Medicine suggest that the transition to ALS is not a sudden event but a gradual biochemical process. Mapping these trajectories provides a framework for identifying the earliest stages of neurodegeneration before irreversible nerve damage occurs.